Global pharma is sourcing innovation from the Asia-Pacific (APAC) region, which is gaining relevance in advanced modalities. With the public sector playing a key role in empowering biotech innovation, Singapore – with its commitment to innovation, stability, intellectual property protection and regulatory alignment – is emerging as an APAC biotech leader.
Produced through a collaboration between Bain & Company, A*STAR, EDB, J.P. Morgan, and SG Growth Capital, the report offers insights for biotech and pharma players, as well as APAC policymakers. Read to learn about:
- Biotech investment trends: Why capital is shifting toward late-stage, lower-risk assets and how public funding is filling early-stage gaps
- Advanced therapeutics and technology platforms: Asia’s growing strengths in mRNA, cell and gene therapy, antibody-drug conjugates (ADCs), and artificial intelligence-led drug discovery
- Global pharma strategy: How geopolitical dynamics and tightening US research budgets are pushing pharma to expand R&D and sourcing in Asia
- How government and the public sector can power biotech ecosystems: These span policy tools, research infrastructure, and talent strategies
- Singapore’s advantage: How the country’s neutrality, IP protection, regulatory strength, and infrastructure are attracting top-tier firms and enabling end-to-end innovation
Access the full paper to gain insight into APAC’s evolving role in global biotech hub.
